Montmorency tart cherry juice lowered blood uric acid levels and a marker for inflammation

Tart cherries have long been researched for their association with pain relief - ranging from gout and arthritis joint pain to exercise-related muscle pain. A new study published in the Journal of Functional Foods is the first to report consumption of Montmorency tart cherries caused changes in uric acid metabolism, which can have an impact on joint pain. The study also detected increases in specific anthocyanin compounds in the bloodstream after consuming tart cherries.

In the study, Montmorency tart cherry juice reduced blood levels of uric acid and C-reactive protein, a measure of inflammation. High levels of uric acid are linked to gout, a form of arthritis that can cause severe attacks of intense pain and swelling (inflammation) in various joints, including the big toe and other joints in the legs and arms.

A research team led by Dr. Glyn Howatson with PhD student Phillip Bell in the Department of Sport, Exercise and Rehabilitation at Northumbria University in the UK gave 12 healthy participants (average age 26 years) two doses of Montmorency tart cherry juice concentrate: about 1 ounce (30 ml) of the juice concentrate mixed with 100 ml of water (equivalent to 90 whole Montmorency tart cherries) or 2 ounces (60 ml) of juice concentrate mixed with 100 ml of water.

The researchers used a single blind, two-phase, randomized, cross-over design to identify the bioavailability of anthocyanins following the consumption of these two different doses. There was a washout period of at least 10 days between the phases. Each phase was comprised of two days drinking the tart cherry juice concentrate twice a day - in the morning and just before dinner.

The researchers collected blood and urine samples from the participants immediately before and at numerous intervals for 48 hours after the tart cherry juice was consumed. The results supported the researchers' hypothesis: blood levels of uric acid and C-reactive protein were reduced and urinary uric acid was increased following both doses of the tart cherry juice. The magnitude of the change was independent of the dose given; that is, the 30 ml of the juice was just as effective as 60 ml.

"We have been investigating Montmorency tart cherries for several years because they're a unique fruit with a high concentration of anthocyanins," said co-author Howatson, whose previous studies have demonstrated the ability of tart cherry juice to reduce certain inflammation responses and oxidative stress after high-intensity exercise. "Our current study was conducted with a healthy population, although more research is needed to determine the specific benefits of Montmorency tart cherry juice for individuals with inflammatory diseases, including gout and other arthritic conditions."

A second study newly published in the Journal of Functional Foods conducted by Dr. E. Mitchell Seymour and Dr. Sara M. Warber from the University of Michigan found that the antioxidant capacity in the blood was elevated after eating whole frozen Montmorency tart cherries (45 or 90 cherries), and remained elevated even 12-hours after eating the 90 cherries. Similar to the Howatson team in the UK, they also observed tart cherry anthocyanin metabolites in the blood and urine with both doses of the whole tart cherries.

"Our observations were after a one-time consumption," said lead author Seymour. "It is compelling to think what could occur with more regular consumption of tart cherries, and how that could translate into possible health benefits."

Montmorency tart cherries are available year-round in dried, frozen and juice forms --including juice concentrate, which was the form used in the UK study. Montmorency tart cherry juice concentrate can be mixed with water or other juices. It can also be consumed straight from the bottle or used as an ingredient in recipes, including smoothies and other beverages.

The Cherry Marketing Institute, a not-for-profit organization, provided financial support for the UK analysis of anthocyanins and high sensitivity C-reactive protein, a marker of inflammation. All other elements of the study were funded by Northumbria University, UK. The funders had no role in the study design, data collection and analysis, decision to publish or preparation of the manuscript. The Seymour et al. study was supported by an unrestricted grant from the Cherry Marketing Institute and the University of Michigan Clinical Research Unit of the Michigan Institute for Clinical and Health Research from the U.S. National Institutes of Health.

For more information on the growing body of research on Montmorency tart cherries, visit https://www.choosecherries.com.

Sources:

Bell PG, Gaze DC, Davison GW, George TW, Scotter MJ, Howatson G. Montmorency tart cherry (Prunus cerasus L.) concentrate lowers uric acid, independent of plasma cyanidin-3-O-glucosiderutinoside. Journal of Functional Foods. 2014; 11: 82-90.

Bell PG, Walshe IH, Davison GW, Stevenson E, Howatson G. Montmorency cherries reduce the oxidative stress and inflammatory responses to repeated days high-intensity stochastic cycling. Nutrients. 2014;6:829-843.

Seymour EM, Warber SM, Kirakosyan A, Noon KR, Gillespie B, Uhley VE, Wunder J, Urcuyo DE, Kaufman PB, Bolling SF. Anthocyanin pharmacokinetics and dose-dependent plasma antioxidant pharmacodynamics following whole tart cherry intake in human adults. Journal of Functional Foods. Sept. 2014; published online ahead of print.